Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Hedy Lee KindlerPascal HammelMichele ReniEric Van CutsemTeresa MacarullaMichael J HallJoon Oh ParkDaniel HochhauserDirk ArnoldDo Youn OhAnke C Reinacher-SchickGiampaolo TortoraHana AlgülEileen M O'ReillySonal BordiaDavid McGuinnessKaren Y CuiGershon Y LockerTalia GolanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.